Publikationen, an denen er mitarbeitet Carlos Matute Almau (32)

2024

  1. Autoimmune inflammation triggers aberrant astrocytic calcium signaling to impair synaptic plasticity

    Brain, Behavior, and Immunity, Vol. 121, pp. 192-210

2023

  1. Endocannabinoid signaling in brain diseases: Emerging relevance of glial cells

    GLIA, Vol. 71, Núm. 1, pp. 103-126

  2. Spatial organization of neuron-astrocyte interactions in the somatosensory cortex

    Cerebral cortex (New York, N.Y. : 1991), Vol. 33, Núm. 8, pp. 4498-4511

  3. The endocannabinoid system and autoimmune demyelination: A focus on multiple sclerosis

    Neurobiology and Physiology of the Endocannabinoid System (Elsevier), pp. 229-240

  4. Therapeutic effect of α7 nicotinic receptor activation after ischemic stroke in rats

    Journal of Cerebral Blood Flow and Metabolism, Vol. 43, Núm. 8, pp. 1301-1316

2022

  1. Cannabinoid CB1 receptor expression in oligodendrocyte progenitors of the hippocampus revealed by the NG2-EYFP-knockin mouse

    Frontiers in Neuroanatomy, Vol. 16

  2. Cannabinoid CB1 receptor gene inactivation in oligodendrocyte precursors disrupts oligodendrogenesis and myelination in mice

    Cell Death and Disease, Vol. 13, Núm. 7

2021

  1. Astrocytic atrophy as a pathological feature of Parkinson’s disease with LRRK2 mutation

    npj Parkinson's Disease, Vol. 7, Núm. 1

  2. Fit-for-purpose based testing and validation of antibodies to amino- and carboxy-terminal domains of cannabinoid receptor 1

    Histochemistry and Cell Biology, Vol. 156, Núm. 5, pp. 479-502

  3. Δ9-Tetrahydrocannabinol promotes functional remyelination in the mouse brain

    British Journal of Pharmacology, Vol. 178, Núm. 20, pp. 4176-4192

  4. Δ9-Tetrahydrocannabinol promotes oligodendrocyte development and CNS myelination in vivo

    GLIA, Vol. 69, Núm. 3, pp. 532-545

2020

  1. Gene expression analysis of astrocyte and microglia endocannabinoid signaling during autoimmune demyelination

    Biomolecules, Vol. 10, Núm. 9, pp. 1-19

  2. P2x7 receptors control demyelination and inflammation in the cuprizone model

    Brain, Behavior, and Immunity - Health, Vol. 4

2018

  1. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination

    Biochemical Pharmacology, Vol. 157, pp. 189-201

  2. Inhibition of Casein Kinase 2 Protects Oligodendrocytes From Excitotoxicity by Attenuating JNK/p53 Signaling Cascade

    Frontiers in Molecular Neuroscience, Vol. 11

  3. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis

    Neuropharmacology, Vol. 141, pp. 181-191

2017

  1. Effects of FTY720 on brain neurogenic niches in vitro and after kainic acid-induced injury

    Journal of Neuroinflammation, Vol. 14, Núm. 1

2016

  1. Possible therapeutic doses of cannabinoid type 1 receptor antagonist reverses key alterations in fragile X syndrome mouse model

    Genes, Vol. 7, Núm. 9

  2. Synaptic plasticity and spatial working memory are impaired in the CD mouse model of Williams-Beuren syndrome

    Molecular Brain, Vol. 9, Núm. 1

2015

  1. Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo

    GLIA, Vol. 63, Núm. 1, pp. 163-176